Why the labels start low
Every schedule below is introduced with the same purpose: to reduce the risk of gastrointestinal adverse reactions [1][2][5][9]. The trial data explain why. In the Ozempic® trials, stomach and bowel reactions affected 32.7% to 36.4% of people on semaglutide against 15.3% on placebo, and most nausea, vomiting and diarrhea occurred during dose escalation [1]. In the Zepbound® weight trials the figures were 56% against 30%, again concentrated in the escalation period and easing over time [5]. The Wegovy® and Foundayo™ labels describe the same timing [2][9].
A second effect sits behind it. The tirzepatide and orforglipron labels say the slowing of stomach emptying is largest after the first dose and lessens with time [5][9]. Starting low gives the body time to adjust before the next increase.
The schedules, label by label
The table restates the starting dose, the steps and the maintenance options in each US label, with the section to check. It explains the labels; it is not a schedule to follow, and your prescriber may use a different one.
| Medicine | Start | Steps in the label | Maintenance the label describes | Section |
|---|---|---|---|---|
| Ozempic® injection [1] | 0.25 mg weekly for 4 weeks | 0.5 mg; then 1 mg and 2 mg, each after at least 4 weeks, if more glucose control is needed | 0.5, 1 or 2 mg weekly | 2.2 |
| Wegovy® injection [2] | 0.25 mg weekly, weeks 1–4 | 0.5, 1 and 1.7 mg, 4 weeks each | 1.7 or 2.4 mg from week 17; up to 7.2 mg for adult weight reduction | 2.2 |
| Wegovy® tablets [2] | 1.5 mg daily, days 1–30 | 4 mg on days 31–60, 9 mg on days 61–90 | 25 mg daily from day 91 | 2.3 |
| Rybelsus® [3] | 3 mg daily, days 1–30 | 7 mg on days 31–60 | 7 mg, or 14 mg from day 61 if more control is needed | 2.2 |
| Ozempic® tablets [3] | 1.5 mg daily, days 1–30 | 4 mg on days 31–60 | 4 mg, or 9 mg from day 61 if more control is needed | 2.2 |
| Mounjaro® [4] | 2.5 mg weekly | +2.5 mg after at least 4 weeks, if more glucose control is needed | Up to 15 mg weekly in adults, 10 mg in children | 2.1 |
| Zepbound® [5] | 2.5 mg weekly for 4 weeks | 5 mg, then +2.5 mg once the current dose has been taken for 4 weeks or more | 5, 10 or 15 mg weekly; 10 or 15 mg for sleep apnea | 2.1–2.2 |
| Trulicity® [6] | 0.75 mg weekly | 1.5 mg after 4 weeks; further 1.5 mg steps after at least 4 weeks, if needed | Up to 4.5 mg weekly in adults, 1.5 mg in children | 2.1–2.2 |
| Victoza® [7] | 0.6 mg daily for 1 week | 1.2 mg; 1.8 mg after at least 1 week, if needed | 1.2 or 1.8 mg daily | 2.1 |
| Saxenda® [8] | 0.6 mg daily in week 1 | 1.2, 1.8 and 2.4 mg, one week each | 3 mg daily from week 5 | 2.2 |
| Foundayo™ [9] | 0.8 mg daily for at least 30 days | 2.5 mg, 5.5 mg, then 9, 14.5 or 17.2 mg, each after at least 30 days | Up to 17.2 mg daily; 9 mg with a strong CYP3A4 inhibitor | 2.1–2.2 |
Starting doses that are not treatment doses
Several labels say outright that the first rung is for getting started. The Rybelsus® 3 mg and Ozempic® tablet 1.5 mg starting doses are described as not effective for blood sugar control, and so is the 0.6 mg Victoza® dose in adults [3][7]. The Zepbound® label describes 2.5 mg as a dose for beginning treatment that is not approved for maintenance, and the Saxenda® label says its lower doses are for titration only [5][8]. The EU Ozempic® document adds that 0.25 mg is not a maintenance dose [15].
Feeling little change at first therefore fits how the schedules are built. When and whether to move up is your prescriber’s call.
When a step is hard to tolerate
- Wegovy® injection: if a dose is not tolerated during escalation, the label suggests considering a 4-week delay before the next step. The maintenance dose, 1.7 or 2.4 mg, is chosen with treatment response and tolerability in mind [2].
- Wegovy® tablets: the label suggests considering a delay in escalation, and if the 25 mg maintenance tablet is not tolerated, a switch to the 1.7 mg weekly injection [2].
- Zepbound®: response and tolerability guide the maintenance dose, and a lower maintenance dose can be considered if one is not tolerated [5].
- Saxenda®: an increase that is not tolerated can be delayed by about one more week; treatment is stopped in adults who cannot tolerate 3 mg. Children may reduce to 2.4 mg, return to the previous level during escalation, and take up to 8 weeks to escalate [8].
- Foundayo™: each step beyond 5.5 mg is made after at least 30 days, based on treatment response and tolerability [9].
- Ozempic®, Mounjaro®, Trulicity® and Victoza®: the trigger for each increase is the need for more blood sugar control, and the US labels add no separate delay wording [1][4][6][7].
How the European documents differ
- Wegovy®: with significant stomach symptoms, delaying escalation or lowering to the previous dose until symptoms improve could be considered. The 7.2 mg dose is limited to adults whose BMI was 30 or more at the start, and the dose goes back to 2.4 mg if 7.2 mg brings no further improvement in weight [10].
- Saxenda®: if the next step is not tolerated for two weeks in a row, stopping treatment should be considered [11].
- Mounjaro®: the dose is raised to 5 mg after 4 weeks, with further 2.5 mg steps after at least 4 weeks if needed; the US Mounjaro® label instead links each increase to glucose control [4][12].
- Trulicity®: there is no starting step. The dose is 0.75 mg on its own or 1.5 mg added to other diabetes medicines, with increases to 3 mg and 4.5 mg after at least 4 weeks if needed [13].
What the trials allowed
The large trials did not force everyone up on a fixed timetable. In the Wegovy® cardiovascular outcomes trial, people who could not tolerate the recommended escalation could stay at a lower dose; in the MASH trial, escalation could be prolonged or people could remain on a lower dose [2]. In several Zepbound® trials, including the sleep apnea studies and the withdrawal trial, doses were escalated over up to 20 weeks to the highest dose each person tolerated, 10 or 15 mg, whereas the two main weight trials used fixed doses [5].
Trial protocols are not instructions for individual patients, but they show that the people who studied these medicines expected some participants to need more time or a lower ceiling.
What is watched around each step
- Kidneys: vomiting or diarrhea can lead to fluid loss, and the labels ask for kidney function to be monitored in people with such reactions, especially when the dose is started or increased [2][5].
- Birth control pills: the Mounjaro® and Zepbound® labels describe extra contraceptive protection during the 4 weeks that follow the first dose and each later increase, and the Foundayo™ label during 30 days, because the pill may be absorbed less reliably [4][5][9].
- Other diabetes medicines: with insulin or a sulfonylurea, the labels say those doses may need lowering to reduce the risk of low blood sugar [1][4].
- Other medicines for Foundayo™: with a strong CYP3A4 inhibitor, the label caps the dose at 9 mg a day [9].
After a break, and why faster is not safer
The climb can start again after missed doses. The Wegovy® label restarts escalation at a lower dose after 2 or more missed weekly injections; Saxenda® and Victoza® restart at 0.6 mg after more than 3 days without a dose; Foundayo™ restarts lower after 7 or more missed tablets in a row [2][7][8][9]. The article on missed doses compares those rules.
Going faster has its own record. The FDA says it has received adverse event reports from people prescribed compounded semaglutide or tirzepatide at doses beyond the approved labels, including raising the amount more quickly than the label schedule; some sought medical care for nausea, vomiting, diarrhea, abdominal pain or constipation [14]. Any change to the pace, in either direction, belongs in a conversation with your clinician.
Ozempic®, Wegovy®, Rybelsus®, Saxenda® and Victoza® are registered trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound® and Trulicity® are registered trademarks and Foundayo™ is a trademark of Eli Lilly and Company. PepLabo is not affiliated with or endorsed by Novo Nordisk or Eli Lilly and Company.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Severe stomach pain that does not go away, with or without vomiting | Your prescriber, right away | Today | Wegovy® Medication Guide; label section 5.2 [2] |
| Vomiting or diarrhea after a dose increase, with signs of losing fluids | Your prescriber | Today | Wegovy® and Zepbound® labels, kidney sections [2][5] |
| Signs of low blood sugar while also taking insulin or a sulfonylurea | Your prescriber | Today | Ozempic® and Mounjaro® labels [1][4] |
| Side effects that make you doubt the next step | Your prescriber, before the step | At your next appointment | Wegovy® and Zepbound® labels, section 2 [2][5] |
